14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RKDA vs DXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Arcadia Biosciences, Inc. (RKDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RKDA carries a Unified Composite Score of 28.0/100 (SELL) at $0.19 (36.6x Forward P/E, -80.2% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).
Technical & Structure Timing Caution: RKDA is currently in a Breakdown options structure phase (RSI 45.8); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RKDA vs DXR. Trailing 12-month operating profitability (RKDA -80.2% vs DXR -5894.3%) and valuation multiples (RKDA 36.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RKDA vs DXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Daxor Corporation (DXR) is the stronger overall head-to-head candidate over Arcadia Biosciences, Inc. (RKDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RKDA carries a Unified Composite Score of 28.0/100 (SELL) at $0.19 (36.6x Forward P/E, -80.2% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Technical & Structure Timing Caution: RKDA is currently in a Breakdown options structure phase (RSI 45.8); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXR leads the Growth & Scale pillar: RKDA posts -0.8% YoY revenue growth and +28.5% YoY earnings growth on $4.7M TTM revenue (34.6% gross margin, -80.2% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, RKDA generates $4.7M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, RKDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.
RKDA screens cheaper on headline valuation multiples. RKDA trades at 36.6x Forward P/E, 36.6x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-79.9% EBITDA margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RKDA (-430.9% ROE) versus DXR (14.2% ROE) capital efficiency.
In options market volatility and institutional positioning, RKDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.27β · 170% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.